Creso Pharma will lead the field of cannabis derived therapeutic grade nutraceutical products for human and animal health.Creso Pharma’s strategy is to develop, register, and commercialise pharmaceutical-grade cannabis- and hemp-based products and treatments, to the highest GMP (Good Manufacturing Practice) quality standards. Our standardised dosing forms and proprietary innovative delivery systems are intended to enhance bioavailability and absorption –specifically designed for several medical conditions. Creso Pharma will leverage science and research in order to develop and commercialise innovative therapeutic approaches, targeting the endocannabinoid system in order to bring vast therapeutic opportunities to human and animal health medicine. We are committed to applying innovative scientific delivery mechanisms that will allow for standardisation of formulation and doses and increase absorption and bioavailability of our safe, high grade CBD GMP Nutraceuticals and Dietary Supplements. By focusing on unique and innovative product delivery mechanisms, Creso Pharma is developing cannabis and hemp therapeutic products, manufactured to the highest pharmaceutical GMP standard and delivered to the highest quality levels across the supply chain. A strong track record of success with ASX listed and global pharmaceutical companies in the development and commercialisation of similar cannabis and hemp-derived products, will be instrumental in Creso Pharma’s management team achieving its ‘go to market strategies. Stand 06.12.2016
WKN: - ISIN: AU000000CPH2 Kürzel: CPH.AX in handelbar: NEIN
Gründungsjahr: 12/2015 Haupthandelsplatz Vollzogene Namenswechsel - Land Angestellte: k.A.